MiCLASP Post-Market Study - Significant MR Reduction. Sustained.

The MiCLASP Post-Market Study 1-Year Outcomes:

Adding to the body of evidence for transcatheter mitral valve repair with the PASCAL system.

In the ongoing MiCLASP
post-market study,
the PASCAL system demonstrated:

favourable safety
sustained MR reduction
at 1 year
significant symptomatic and quality-of-life improvements

MR = Mitral regurgitation

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, CLASP, Edwards PASCAL and PASCAL are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates.

All other trademarks are the property of their respective owners.

Privacy Policy

© 2023 Edwards Lifesciences Corporation. All rights reserved. PP--EU-5803 v1.0

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com

Page Title

Page Title

heading 2

heading 3

heading 3